Microfluidic cell-squeezing device opens new possibilities for cell-based vaccines
MIT researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune system’s B cells, providing a new approach to developing and implementing antigen-presenting cell vaccines.
Such vaccines, created by reprogramming a patient’s own immune cells to fight invaders, hold great promise for treating cancer and other diseases. However, several inefficiencies have limited their translation to the clinic, and only one therapy has been approved by the Food and Drug Administration.
While most of these vaccines are created with dendritic cells, a class of antigen-presenting cells with broad functionality in the immune system, the researchers demonstrate in a study published in Scientific Reports that B cells can be engineered to serve as an alternative.
“We wanted to remove an important barrier in using B cells as an antigen-presenting cell population, helping them complement or replace dendritic cells,” says Gregory Szeto, a postdoc at MIT’s Koch Institute for Integrative Cancer Research and the paper’s lead author.
Darrell Irvine, a member of the Koch Institute and a professor of biological engineering and of materials sciences and engineering, is the paper’s senior author.
A new vaccine-preparation approach
Dendritic cells are the most naturally versatile antigen-presenting cells. In the body, they continuously sample antigens from potential invaders, which they process and present on their cell surface. The cells then migrate to the spleen or the lymph nodes, where they prime T cells to mount an attack against cells that are cancerous or infected, targeting the specific antigens that are ingested and presented.
Despite their critical role in the immune system, dendritic cells have drawbacks when used for cell-based vaccines: They have a short lifespan, they do not divide when activated, and they are relatively sparse in the bloodstream.
B cells are also antigen-presenting cells, but in contrast to dendritic cells, they can proliferate when activated and are abundant in the bloodstream. However, their functionality is more limited: Whereas dendritic cells constantly sample antigens they encounter, a B cell is genetically programmed only to bind to a specific antigen that matches the receptor on its surface. As such, a B cell generally will not ingest and display an antigen if it does not match its receptor.
Using a microfluidic device, MIT researchers were able to overcome this genetically programmed barrier to antigen uptake — by squeezing the B cells.
Through “CellSqueeze,” the device platform originally developed at MIT, the researchers pass a suspension of B cells and target antigen through tiny, parallel channels etched on a chip. A positive-pressure system moves the suspension through these channels, which gradually narrow, applying a gentle pressure to the B cells. This “squeeze” opens small, temporary holes in their membranes, allowing the target antigen to enter by diffusion.
This process effectively loads the cells with antigens to prime a response of CD8 — or “killer” — T cells, which can then kill cancer cells or other target cells.
Read more: Freshly squeezed vaccines
The Latest on: Cell-based vaccines
[google_news title=”” keyword=”Cell-based vaccines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cell-based vaccines
- Could Cancer Vaccines Be the Next Big Breakthrough in Immunotherapy?on May 12, 2024 at 9:34 pm
The race is on to develop therapeutic cancer vaccines that could give immunotherapies an edge, and late-stage trials could soon provide more-robust data about candidates’ efficacy and safety.
- COVID-19 vaccines for kids: What you need to knowon May 12, 2024 at 5:45 am
Learn about the safety and effectiveness of COVID-19 vaccines for kids, the possible side effects, and the benefits of vaccination.
- How mRNA vaccines could be personalized cancer cureson May 7, 2024 at 2:30 am
An expanding pipeline of vaccines is giving patients new hope against some of the deadliest cancers, by training the body's immune system to attack malignancies. Why it matters: This personalized ...
- Expanding a lymph node, boosting a vaccineon May 6, 2024 at 2:41 am
For the first time, researchers from the Wyss Institute for Biologically Inspired Engineering at Harvard University, Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS), ...
- New influenza vaccine strategies aim to enhance protection with T-cell responseson May 5, 2024 at 11:13 pm
A recent review highlights the need for innovative influenza vaccines that combine T-cell and antibody responses to enhance protection across multiple strains and seasons.
- New approach for developing cancer vaccines could make immunotherapies more effective in acute myeloid leukemiaon May 3, 2024 at 12:13 pm
Acute myeloid leukemia (AML) is a type of blood cancer that forms in the soft marrow of the bones, typically attacking cells that would otherwise form the key component of the body's immunodefense ...
- MRNA vaccine effective in treating glioblastoma brain cancer in small trialon May 2, 2024 at 9:24 am
An experimental cancer vaccine can quickly reprogram a person's immune system to attack glioblastoma, the most aggressive and lethal form of brain cancer, a small, preliminary study has found.
- CSL : Real-World Evidence Study Proves Effectiveness Of Cell-Based Quadrivalent Influenza Vaccineson May 2, 2024 at 7:42 am
(RTTNews) - CSL Seqirus, a subsidiary of CSL Ltd. (CSL.AX), Thursday said that a real-world evidence study shows that a cell-based quadrivalent influenza vaccine has been more effective than an ...
- New mRNA Vaccines in Development for Cancer and Infectionson May 2, 2024 at 2:22 am
Prelog also discussed personalized vaccines for cancer immunotherapy. Personalized mRNA vaccines are tailored to the patient's genetic characteristics and antigens. They could be used in cancer ...
- Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasonson May 2, 2024 at 1:45 am
The study suggests that cell-based quadrivalent influenza vaccine (QIVc) may have the potential to be more effective than egg-based vaccines (QIVe) in preventing test-confirmed influenza.
via Bing News